NASDAQ:ICPT

Intercept Pharmaceuticals (ICPT) Stock Forecast, Price & News

$10.48

-0.32 (-2.96%)

(As of 09/22/2023 ET)

Compare

Today's Range: $9.85
▼
$10.74
50-Day Range: $9.99
▼
$11.86
52-Week Range: $8.82
▼
$21.86

Volume: 1.31 million shs
Average Volume: 892,724 shs
Market Capitalization: $437.85 million

P/E Ratio: 1.64
Dividend Yield: N/A
Price Target: $22.36

Intercept Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 113.4% Upside
$22.36 Price Target
Short Interest: Bearish
29.02% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.13
Upright™ Environmental Score
News Sentiment: 0.30
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.06) to $2.27 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

493rd out of 963 stocks

Pharmaceutical Preparations Industry

226th out of 458 stocks

3.3

Analyst's Opinion

Consensus Rating
Intercept Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $22.36, Intercept Pharmaceuticals has a forecasted upside of 113.4% from its current price of $10.48.
Amount of Analyst Coverage
Intercept Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
29.02% of the float of Intercept Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Intercept Pharmaceuticals has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Intercept Pharmaceuticals has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Intercept Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Intercept Pharmaceuticals does not have a long track record of dividend growth.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intercept Pharmaceuticals has received a 53.13% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Liver-disease medication (A05)", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Intercept Pharmaceuticals is -2.13.

1.8

News and Social Media Coverage

News Sentiment
Intercept Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Intercept Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for ICPT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Intercept Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intercept Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.20% of the stock of Intercept Pharmaceuticals is held by insiders.
Percentage Held by Institutions
83.81% of the stock of Intercept Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Intercept Pharmaceuticals are expected to grow in the coming year, from ($1.06) to $2.27 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intercept Pharmaceuticals is 1.64, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 108.90.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intercept Pharmaceuticals is 1.64, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 99.71.
Price to Book Value per Share Ratio
Intercept Pharmaceuticals has a P/B Ratio of 4.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intercept Pharmaceuticals (NASDAQ:ICPT) Stock

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey.

ICPT Price History

30 days | 90 days | 365 days | Advanced Chart

ICPT Stock News Headlines

September 22, 2023 | americanbankingnews.com

Zacks Research Weighs in on Intercept Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ICPT)

September 21, 2023 | americanbankingnews.com

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Rating of "Moderate Buy" by Brokerages

September 24, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

September 21, 2023 | americanbankingnews.com

FY2025 EPS Estimates for Intercept Pharmaceuticals, Inc. Raised by Zacks Research (NASDAQ:ICPT)

September 20, 2023 | americanbankingnews.com

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Sees Significant Growth in Short Interest

September 9, 2023 | markets.businessinsider.com

Intercept Pharma (ICPT) Receives a Hold from RBC Capital

September 8, 2023 | finance.yahoo.com

Why CymaBay Therapeutics Stock Is Jumping Today

September 7, 2023 | finance.yahoo.com

Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?

September 24, 2023 | Behind the Markets (Ad)

BREAKING: The truth about war with China

Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.

September 1, 2023 | finance.yahoo.com

Why Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?

August 4, 2023 | msn.com

Canaccord Genuity Maintains Intercept Pharmaceuticals (ICPT) Buy Recommendation

August 2, 2023 | finanznachrichten.de

Intercept Pharmaceuticals, Inc.: Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 2, 2023 | finance.yahoo.com

Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 2, 2023 | finance.yahoo.com

Intercept (ICPT) Q2 Earnings Top Estimates, Revenues Up Y/Y

July 26, 2023 | finance.yahoo.com

Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023

July 26, 2023 | finance.yahoo.com

Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

July 13, 2023 | msn.com

HC Wainwright & Co. Upgrades Intercept Pharmaceuticals (ICPT)

July 13, 2023 | markets.businessinsider.com

Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business

July 13, 2023 | msn.com

Intercept Pharma gains on H.C. Wainwright double upgrade

July 13, 2023 | markets.businessinsider.com

Positive Report for Intercept Pharma (ICPT) from H.C. Wainwright

July 11, 2023 | markets.businessinsider.com

RBC Capital Keeps Their Hold Rating on Intercept Pharma (ICPT)

July 6, 2023 | msn.com

Intercept Pharmaceuticals (ICPT) Price Target Decreased by 24.23% to 14.62

June 29, 2023 | finance.yahoo.com

Biotech Stock Roundup: SRPT's DMD Therapy Approval, ICPT's Setback & More Updates

June 26, 2023 | msn.com

RBC Capital Maintains Intercept Pharmaceuticals (ICPT) Sector Perform Recommendation

June 26, 2023 | finance.yahoo.com

Intercept (ICPT) to Restructure Operations, Cut Workforce

June 26, 2023 | markets.businessinsider.com

Bank of America Securities Reaffirms Their Sell Rating on Intercept Pharma (ICPT)

June 24, 2023 | markets.businessinsider.com

Intercept Pharma To Cut Jobs

See More Headlines

Receive ICPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ICPT Company Calendar

Last Earnings: 8/02/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ICPT
CUSIP: 45845P10
CIK: 1270073
Web: www.interceptpharma.com
Phone: (646) 747-1000
Fax: 646-747-1001
Employees: 341
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.36
High Stock Price Forecast: $54.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +113.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.39
Trailing P/E Ratio: 1.64
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $221.82 million
Net Margins: 68.07%
Pretax Margin: -51.82%
Return on Equity: -189.98%
Return on Assets: -30.32%

Debt

Debt-to-Equity Ratio: 3.31
Current Ratio: 2.52
Quick Ratio: 2.52

Sales & Book Value

Annual Sales: $285.71 million
Price / Sales: 1.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.25 per share
Price / Book: 4.66

Miscellaneous

Outstanding Shares: 41,780,000
Free Float: 39,192,000
Market Cap: $437.85 million
Optionable: Optionable
Beta: 1.22

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Jerome B. Durso (Age 55)
Pres, CEO & Director
Comp: $1.37M

Mr. Andrew Saik (Age 54)
Chief Financial Officer
Comp: $888.6k

Mr. Jared M. Freedberg J.D. (Age 55)
Gen. Counsel
Comp: $812.55k

Ms. Linda M. Richardson (Age 59)
Exec. VP & Chief Commercial Officer
Comp: $837.73k

Dr. M. Michelle Berrey M.D. (Age 56)
M.P.H., MPH., Pres of R&D and Chief Medical Officer
Comp: $1.12M

Mr. Rocco Venezia (Age 47)
Chief Accounting Officer & Treasurer

Mr. Nareg Sagherian
Exec. Director of Global Investor Relations

Mr. David Ford (Age 53)
Chief HR Officer

Dr. Mark Pruzanski M.D. (Age 55)
Founder, Advisor & Director

Paul Nitschmann
Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ICPT Stock - Frequently Asked Questions

Should I buy or sell Intercept Pharmaceuticals stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ICPT shares.
View ICPT analyst ratings or view top-rated stocks.
What is Intercept Pharmaceuticals' stock price forecast for 2023?: 8 Wall Street analysts have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their ICPT share price forecasts range from $13.00 to $54.00. On average, they anticipate the company's stock price to reach $22.36 in the next year. This suggests a possible upside of 113.4% from the stock's current price.
View analysts price targets for ICPT or view top-rated stocks among Wall Street analysts.
How have ICPT shares performed in 2023?: Intercept Pharmaceuticals' stock was trading at $12.37 on January 1st, 2023. Since then, ICPT shares have decreased by 15.3% and is now trading at $10.48.
View the best growth stocks for 2023 here.
Are investors shorting Intercept Pharmaceuticals?: Intercept Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 10,400,000 shares, an increase of 9.2% from the August 15th total of 9,520,000 shares. Based on an average daily trading volume, of 986,900 shares, the days-to-cover ratio is currently 10.5 days. Currently, 29.0% of the company's stock are short sold.
View Intercept Pharmaceuticals' Short Interest.
When is Intercept Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ICPT earnings forecast.
How were Intercept Pharmaceuticals' earnings last quarter?: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company earned $83.70 million during the quarter, compared to analyst estimates of $79.57 million. Intercept Pharmaceuticals had a negative trailing twelve-month return on equity of 189.98% and a net margin of 68.07%. Intercept Pharmaceuticals's revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.68) EPS.
What ETF holds Intercept Pharmaceuticals' stock ?: Virtus LifeSci Biotech Products ETF holds 28,540 shares of ICPT stock, representing 1.65% of its portfolio.
What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?: Intercept Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $320.00 million-$340.00 million, compared to the consensus revenue estimate of $320.39 million.

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?: 32 employees have rated Intercept Pharmaceuticals Chief Executive Officer Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Intercept Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).
What is Intercept Pharmaceuticals' stock symbol?: Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
Who are Intercept Pharmaceuticals' major shareholders?: Intercept Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.52%), State Street Corp (10.01%), Renaissance Technologies LLC (2.10%), Boothbay Fund Management LLC (0.00%), Rockefeller Capital Management L.P. (1.86%) and Geode Capital Management LLC (1.47%). Insiders that own company stock include Sandip Kapadia and Srinivas Akkaraju.
View institutional ownership trends.
How do I buy shares of Intercept Pharmaceuticals?: Shares of ICPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Intercept Pharmaceuticals' stock price today?: One share of ICPT stock can currently be purchased for approximately $10.48.
How much money does Intercept Pharmaceuticals make?: Intercept Pharmaceuticals (NASDAQ:ICPT) has a market capitalization of $437.85 million and generates $285.71 million in revenue each year. The biopharmaceutical company earns $221.82 million in net income (profit) each year or $6.39 on an earnings per share basis.
How many employees does Intercept Pharmaceuticals have?: The company employs 341 workers across the globe.
How can I contact Intercept Pharmaceuticals?: Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The official website for the company is www.interceptpharma.com. The biopharmaceutical company can be reached via phone at (646) 747-1000, via email at investors@interceptpharma.com, or via fax at 646-747-1001.

This page (NASDAQ:ICPT) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial